Michelle Dipp
Encyclopedia
Michelle Dipp, M.D., Ph.D., is a co-founder and CEO of OvaScience, a company focused on improving the success of IVF
, as well as a founder and partner of Longwood Fund, a healthcare venture capital firm that founds and invests in healthcare companies..
along with fertility expert and Harvard Medical School Professor Jonathan Tilly, Ph.D. of Massachusetts General Hospital, and aging expert and Harvard Medical School Professor David Sinclair, Ph.D.
In February 2010, it was announced that Dipp, along with Christoph Westphal
and Richard Aldrich, launched a venture capital firm, Longwood Founders Fund LP.
Prior to launching Longwood Founders Fund in February 2010, Dipp was the senior vice president and head of the Centre of Excellence for External Drug Discovery (ceedd) at GlaxoSmithKline (GSK). Dipp and Christoph Westphal resigned their positions on the board of the Healthy Lifespan Institute.
Prior to managing GSK’s ceedd, Dipp was the vice president of corporate development at Sirtris, which is developing new drug candidates that target the sirtuins—a recently discovered family of enzymes that appear to control aging—to treat diseases of aging, including Type 2 Diabetes, inflammatory diseases and cancer. Founded in 2004 by Christoph Westphal
and David Sinclair
, Sirtris was one of the first pharmaceutical companies focused on the sirtuin platform. Dipp led the acquisition of Sirtris by GSK in 2008 for $720 million.
Before joining Sirtris as a founding employee, Dipp worked in health care private equity at The Wellcome Trust, London. Dipp did her post-doctoral research in the departments of Pharmacology and Cardiothoracic Surgery, John Radcliffe Hospital
, Oxford. She is the author of a recently published book titled "Pulmonary Hypertension and Hypopxic Pulmonary Vasoconstriction". She holds an M.D. and a Ph.D. in pulmonary physiology from the University of Oxford
.
In vitro fertilisation
In vitro fertilisation is a process by which egg cells are fertilised by sperm outside the body: in vitro. IVF is a major treatment in infertility when other methods of assisted reproductive technology have failed...
, as well as a founder and partner of Longwood Fund, a healthcare venture capital firm that founds and invests in healthcare companies..
Career
Dipp is currently the CEO of OvaScience, a fertility company trying to improve the quality of eggs and increase the success of in vitro fertilization. Dipp co-founded the company in 2011 along with Richard Aldrich and Christoph Westphal M.D., Ph.D., of Longwood Fund,along with fertility expert and Harvard Medical School Professor Jonathan Tilly, Ph.D. of Massachusetts General Hospital, and aging expert and Harvard Medical School Professor David Sinclair, Ph.D.
In February 2010, it was announced that Dipp, along with Christoph Westphal
Christoph Westphal
Christoph Westphal, M.D., Ph.D., co-founded Sirtris Pharmaceuticals in 2004 with David Sinclair and served as Chief Executive Officer until April 2010. Dr...
and Richard Aldrich, launched a venture capital firm, Longwood Founders Fund LP.
Prior to launching Longwood Founders Fund in February 2010, Dipp was the senior vice president and head of the Centre of Excellence for External Drug Discovery (ceedd) at GlaxoSmithKline (GSK). Dipp and Christoph Westphal resigned their positions on the board of the Healthy Lifespan Institute.
Prior to managing GSK’s ceedd, Dipp was the vice president of corporate development at Sirtris, which is developing new drug candidates that target the sirtuins—a recently discovered family of enzymes that appear to control aging—to treat diseases of aging, including Type 2 Diabetes, inflammatory diseases and cancer. Founded in 2004 by Christoph Westphal
Christoph Westphal
Christoph Westphal, M.D., Ph.D., co-founded Sirtris Pharmaceuticals in 2004 with David Sinclair and served as Chief Executive Officer until April 2010. Dr...
and David Sinclair
David Sinclair (biologist)
David A. Sinclair PhD is a biologist best known for his research on the biology of lifespan extension and driving research towards treating diseases of ageing.-Current position:...
, Sirtris was one of the first pharmaceutical companies focused on the sirtuin platform. Dipp led the acquisition of Sirtris by GSK in 2008 for $720 million.
Before joining Sirtris as a founding employee, Dipp worked in health care private equity at The Wellcome Trust, London. Dipp did her post-doctoral research in the departments of Pharmacology and Cardiothoracic Surgery, John Radcliffe Hospital
John Radcliffe Hospital
The John Radcliffe Hospital is a large tertiary teaching hospital in Oxford, England.It is the main teaching hospital for Oxford University and Oxford Brookes University. As such, it is a well-developed centre of medical research. It also incorporates the Medical School of the University of Oxford....
, Oxford. She is the author of a recently published book titled "Pulmonary Hypertension and Hypopxic Pulmonary Vasoconstriction". She holds an M.D. and a Ph.D. in pulmonary physiology from the University of Oxford
University of Oxford
The University of Oxford is a university located in Oxford, United Kingdom. It is the second-oldest surviving university in the world and the oldest in the English-speaking world. Although its exact date of foundation is unclear, there is evidence of teaching as far back as 1096...
.
Honors
- 2010 Mass High Tech Women to Watch
- Boston Business JournalBoston Business JournalThe Boston Business Journal is a weekly, business-oriented newspaper published in Boston, Massachusetts. It is published by the American City Business Journals....
40-under-40 honoree (2009) - Recognition as an Emerging Pharma Leader by Pharmaceutical Executive magazine (2009)
- PharmaVOICE 100, a list of the 100 most inspiring people in the life-sciences industry (2009)
- Stevie Award for Women in Business in the category of Best Executive of a non-services business under 100 employees (2008)
- Tech Dealmaker of the Year Award in the category of Life Sciences Mergers and Acquisitions (2008)